Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

YAP promotes erlotinib resistance in human non-small cell lung cancer cells

Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 121

Molecular pathology of lung cancer: current status and perspectives

Oberndorfer, F., & Müllauer, L. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000429 · Cited by 122

Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy

Vaghasiya, K., Ray, E., Singh, R., Jadhav, K., Sharma, A., Khan, R., Katare, O. P., & Verma, R. K. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112027 · Cited by 119

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems

Qu, X., Liu, H., Song, X., Sun, N., Zhong, H., Qiu, X., Yang, X., & Jiang, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113328 · Cited by 120

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations

Kato, Y., Peled, N., Wynes, M. W., Yoshida, K., Pardo, M., Mascaux, C., Ohira, T., Tsuboi, M., Matsubayashi, J., Nagao, T., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e9da60 · Cited by 118

Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer

Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 122

Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer

Shen, H., Zhu, F., Liu, J., Xu, T., Pei, D., Wang, R., Qian, Y., Li, Q., Wang, L., Shi, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103305 · Cited by 116

EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Chalela, R., Curull, V., Enríquez-Rodríguez, C. J., Pijuán, L., Bellosillo, B., & Gea, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.20 · Cited by 119

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing

Kohsaka, S., Petronczki, M. P., Solca, F., & Maemondo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0736 · Cited by 123

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells

Milligan, S. A., Burke, P., Coleman, D. T., Bigelow, R. L. H., Steffan, J. J., Carroll, J. L., Williams, B. J., & Cardelli, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0109 · Cited by 118

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115

Molecular Dependence of Estrogen Receptor–Negative Breast Cancer on a Notch-Survivin Signaling Axis

Lee, C. W., Raskett, C. M., Prudovsky, I. A., & Altieri, D. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6673 · Cited by 115

A functional Notch–survivin gene signature in basal breast cancer

Lee, C. W., Simin, K. J., Liu, Q., Plescia, J., Guha, M., Khan, A. A., Hsieh, C., & Altieri, D. C. (2008) · Breast Cancer Research · doi:10.1186/bcr2200 · Cited by 118

Emerging Role of mTOR in the Response to Cancer Therapeutics

Ilagan, E., & Manning, B. D. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.03.008 · Cited by 118

A new era of long-read sequencing for cancer genomics

Sakamoto, Y., Sereewattanawoot, S., & Suzuki, A. (2019) · Journal of Human Genetics · doi:10.1038/s10038-019-0658-5 · Cited by 115

Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis

Kawahara, A., Yamamoto, C., Nakashima, K., Azuma, K., Hattori, S., Kashihara, M., Aizawa, H., Basaki, Y., Kuwano, M., Kage, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3239 · Cited by 114

A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma

Guo, G., Gong, K., Ali, S., Ali, N., Shallwani, S., Hatanpaa, K. J., Pan, E., Mickey, B., Burma, S., Wang, D. H., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4584 · Cited by 116

The past, present, and future of CRM1/XPO1 inhibitors

Wang, A. Y., & Liu, H. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.02.03 · Cited by 114

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Harandi, A., Zaidi, A., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116

Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer

Kitamura, A., Hosoda, W., Sasaki, E., Mitsudomi, T., & Yatabe, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0129 · Cited by 112

TRAF4 Is a Critical Molecule for Akt Activation in Lung Cancer

Li, W., Peng, C., Lee, M., Lim, D., Zhu, F., Fu, Y., Yang, G., Sheng, Y., Xiao, L., Dong, X., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0913 · Cited by 112

Cancer stem cells and immunoresistance: clinical implications and solutions.

Codony‐Servat, J., & Rosell, R. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.12.11 · Cited by 112

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib

Sorensen, S. F., Demuth, C., Weber, B., Sørensen, B. S., & Meldgaard, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.08.001 · Cited by 114

Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer

He, C., Liu, M., Zhou, C., Zhang, J., Ouyang, M., Zhong, N., & Xu, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24653 · Cited by 111

Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis

McCourt, C., McArt, D. G., Mills, K., Catherwood, M. A., Maxwell, P., Waugh, D. J. J., Hamilton, P., O’Sullivan, J. M., & Salto‐Tellez, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069604 · Cited by 111

Preparation of DNA from cytological material

Dejmek, A., Zendehrokh, N., Tomaszewska, M., & Edsjö, A. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21276 · Cited by 112

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Toki, M. I., Mani, N. L., Smithy, J. W., Liu, Y., Altan, M., Wasserman, B. E., Tuktamyshov, R., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.012 · Cited by 114

Delphinidin Reduces Cell Proliferation and Induces Apoptosis of Non-Small-Cell Lung Cancer Cells by Targeting EGFR/VEGFR2 Signaling Pathways

Pal, H. C., Sharma, S., Strickland, L. R., Agarwal, J., Athar, M., Elmets, C. A., & Afaq, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077270 · Cited by 111

Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance

Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110

Exploiting synthetic lethal interactions for targeted cancer therapy

Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110

Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency

Wu, C.-H., Coumar, M. S., Chu, C.-Y., Lin, W., Chen, Y., Chen, C.-T., Shiao, H., Rafi, S., Wang, S.-Y., Hsu, H., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100607r · Cited by 110

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Bria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A. J., Scagliotti, G. V., Cognetti, F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq742 · Cited by 110

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer

Song, Z., Yang, G., Wang, C., Huang, S., Shu, X. H., Liu, K., Zhou, Y., & Ma, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00840 · Cited by 110

Design and synthesis of selective degraders of EGFRL858R/T790M mutant

Zhang, X., Xu, F., Tong, L., Zhang, T., Xie, H., Lu, X., Ren, X., & Ding, K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112199 · Cited by 110

Molecular sputum analysis for the diagnosis of lung cancer

Hubers, A. J., Prinsen, C., Sozzi, G., Lissenberg-Witte, B. I., & Thunnissen, E. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.393 · Cited by 109

EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy

Milanezi, F., Carvalho, S., & Schmitt, F. C. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.417 · Cited by 109

Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines

Suzuki, A., Makinoshima, H., Wakaguri, H., Esumi, H., Sugano, S., Kohno, T., Tsuchihara, K., & Suzuki, Y. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku885 · Cited by 109

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

Azuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 108

Unraveling the molecular genetics of head and neck cancer through genome-wide approaches

Riaz, N., Morris, L. G. T., Lee, W., & Chan, T. A.-T. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.002 · Cited by 111

EGF enhances the migration of cancer cells by up-regulation of TRPM7

Gao, H., Chen, X., Du, X., Guan, B., Liu, Y., & Zhang, H. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.09.003 · Cited by 110

DrugMap: A quantitative pan-cancer analysis of cysteine ligandability

Takahashi, M., Chong, H. B., Zhang, S., Yang, T.-Y., Lazarov, M. J., Harry, S. A., Maynard, M., Hilbert, B. J., White, R. D., Murrey, H. E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.027 · Cited by 110

Diarrhea associated with afatinib: an oral ErbB family blocker

Yang, J. C., Reguart, N., Barinoff, J., Köhler, J., Uttenreuther‐Fischer, M., Stammberger, U. M., O’Brien, D., Wolf, J., & Cohen, E. E. W. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.31 · Cited by 107

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

Wang, Z., Martı́n, D., Molinolo, A., Patel, V., Iglesias‐Bartolomé, R., Degese, M. S., Vitale-Cross, L. A., Chen, Q., & Gutkind, J. S. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju215 · Cited by 106

Lung Injury and Lung Cancer Caused by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms and Therapeutic Opportunities Involving the Ceramide-Generating Machinery and Epidermal Growth Factor Receptor

Goldkorn, T., Filosto, S., & Chung, S. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5469 · Cited by 106

Lung cancer: Prevalent trends & emerging concepts

Raina, V., & Malik, P. S. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.154479 · Cited by 109

Lung cancer in never smokers: Change of a mindset in the molecular era

Lee, Y. J., Kim, J.-H., Kim, S. I., Ha, S., Mok, T. S. K., Mitsudomi, T., & Cho, B. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.013 · Cited by 107

Use of molecular markers for predicting therapy response in cancer patients

Duffy, M. J., O’Donovan, N., & Crown, J. P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.004 · Cited by 107

Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation

Zhang, B., Xu, C., Shao, Y., Wang, H., WU, Y.-F., Ye-ying, S., LI, X.-B., Zhang, Z., Wang, W. P., Li, L., et al. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2221 · Cited by 105

Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer

VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J., Harris, C. C., Deng, J., Calvert, V. S., Silvestri, A., Fredolini, C., Chandhoke, V., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800204-mcp200 · Cited by 106

Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

Hu, C., Leche, C. A., Kiyatkin, A. B., Yu, Z., Stayrook, S. E., Ferguson, K. M., & Lemmon, M. A. (2022) · Nature · doi:10.1038/s41586-021-04393-3 · Cited by 106

Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance

Hopewell, E. L., Zhao, W., Fulp, W. J., Bronk, C. C., Lopez, A. S., Massengill, M. T., Antonia, S. J., Celis, E., Haura, E. B., Enkemann, S. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67250 · Cited by 105

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104

Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment

Han, S., Kim, H., Jeon, Y. K., Oh, D., Lee, S., Kim, D., Im, S., Chung, D. H., Heo, D. S., Bang, Y., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.11.014 · Cited by 103

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

Coudert, B. P., Ciuleanu, T., Park, K., Wu, Y.-L. L. C., Giaccone, G., Brugger, W., Gopalakrishna, P., & Cappuzzo, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr125 · Cited by 104

miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer

Xue, X., Fei, X., Hou, W., Zhang, Y., Liu, L., & Hu, R. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.024 · Cited by 103

The Role of the Apoptotic Machinery in Tumor SuppressionPreprint

Delbridge, A. R. D., Valente, L. J., & Strasser, A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008789 · Cited by 106

miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1

Zhou, G., Fangli, Z., Yu, G., Huang, J., Xie, Y., Yue, S., Chen, M., Jiang, H., & Li, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.100 · Cited by 102

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry

Angulo, B., Conde, E., Suárez‐Gauthier, A., Plaza, C., Martínez, R., Redondo, P., Izquierdo, E., Rubio‐Viqueira, B., Paz-Ares, L. G., Hidalgo, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043842 · Cited by 101

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR , KRAS and ALK gene abnormalities

Gaughan, E. M., & Costa, D. B. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010397569 · Cited by 104

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

Kuan, F.-C., Kuo, L.-T., Chen, M.-C., Yang, C.-T., Shi, C.-S., Teng, D., & Lee, K.-D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.356 · Cited by 101

Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics

Mitchell, R. A., Luwor, R. B., & Burgess, A. W. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.08.009 · Cited by 101

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2022) · Cancers · doi:10.3390/cancers14051321 · Cited by 104

Lung cancer cytology: potential pitfalls and mimics - a review.

Idowu, M. O., & Powers, C. N. (2010) · Europe PMC (PubMed Central) · Cited by 101

Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma

Sirica, A. E. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.7033 · Cited by 105

EPMA position paper in cancer: current overview and future perspectives

Grech, G., Zhan, X., Yoo, B. C., Bubnov, R. V., Hagan, S., Danesi, R., Vittadini, G., & Desiderio, D. M. (2015) · The EPMA Journal · doi:10.1186/s13167-015-0030-6 · Cited by 104

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

Pennell, N. A., & Lynch, T. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0276 · Cited by 100

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

Santarpía, M., Liguori, A., Karachaliou, N., González‐Cao, M., Daffinà, M. G., D’Aveni, A., Marabello, G., Altavilla, G., & Rosell, R. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s119644 · Cited by 104

Development and characterisation of acquired radioresistant breast cancer cell lines

Gray, M., Turnbull, A., Ward, C., Meehan, J., Martínez-Pérez, C., Bonello, M., Pang, L. Y., Langdon, S. P., Kunkler, I. H., Murray, A., et al. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1268-2 · Cited by 103

Electrochemical Biosensors for Cancer Biomarker Detection

Li, J., Li, S., & Yang, C. F. (2012) · Electroanalysis · doi:10.1002/elan.201200447 · Cited by 100

Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites

Diederichs, S., Jung, S., Rothenberg, S. M., Smolen, G. A., Mlody, B., & Haber, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800803105 · Cited by 101

Epidermal growth factor receptor in non-small cell lung cancer.

Prabhakar, C. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.01 · Cited by 103

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations

Shen, Y.-C., Tseng, G.-C., Tu, C.-Y., Chen, W.-C., Liao, W.-C., Chen, W.-C., Li, C.-H., Chen, H.-J., & Hsia, T.-C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.007 · Cited by 99

Potential clinical application of lncRNAs in non-small cell lung cancer

Lu, T., Wang, Y., Chen, D., Liu, J., & Jiao, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s178431 · Cited by 99

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer

Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 103

Quantifying EGFR Alterations in the Lung Cancer Genome with Nanofluidic Digital PCR Arrays

Wang, J., Ramakrishnan, R., Tang, Z., Fan, W., Kluge, A., Dowlati, A., Jones, R. C., & Ma, P. C. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.134973 · Cited by 99

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98

Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR

Santis, G., Angell, R., Nickless, G., Quinn, A., Herbert, A., Cane, P., Spicer, J. F., Breen, R. A. M., McLean, E., & Tobal, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025191 · Cited by 99

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

Bertotti, A., Burbridge, M. F., Gastaldi, S., Galimi, F., Torti, D., Médico, E., Giordano, S., Corso, S., Rolland-Valognes, G., Lockhart, B. P., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000643 · Cited by 103

Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway

Li, W., Ma, X., Li, N., Liu, H., Dong, Q., Zhang, J., Yang, C., Liu, Y., Liang, Q., Zhang, S., et al. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.11.002 · Cited by 98

Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT

Yeh, H. H., Ogawa, K., Balatoni, J., Mukhapadhyay, U., Pal, A., González-Lepera, C., Shavrin, A., Soghomonyan, S., Flores, L. G., Young, D. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010744108 · Cited by 98

Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria

Wu, T., Geng, J., Guo, W., Gao, J., & Zhu, X. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.04.003 · Cited by 101

Discovery of N-((3 R,4 R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97

Epigenome-Based Personalized Medicine in human Cancer

Yan, W., Herman, J. G., & Guo, M. (2015) · Epigenomics · doi:10.2217/epi.15.84 · Cited by 98

Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers

Lee, S. Y., Kim, M. J., Jin, G., Yoo, S. S., Park, J. Y., Choi, J. E., Jeon, H. S., Cho, S., Lee, E. B., Cha, S. I., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f0beca · Cited by 97

Sox2 Expression in Pulmonary Non-small Cell and Neuroendocrine Carcinomas

Sholl, L. M., Long, K. B., & Hornick, J. L. (2009) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181b16b88 · Cited by 97

Tumor Cell Dependence on Ran-GTP–Directed Mitosis

Xia, F., Lee, C. W., & Altieri, D. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5279 · Cited by 97

Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer

Ma, L., Wen, Z.-S., Liu, Z., Hu, Z., Ma, J., Chen, X.-Q., Liu, Y.-Q., Pu, J.-X., Xiao, W.-L., Sun, H.-D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020159 · Cited by 96

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

Leduc, C., Merlio, J. P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P. P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx404 · Cited by 96

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Zhao, Q., Shentu, J., Xu, N., Zhou, J., Yang, G., Yao, Y., Tan, F., Liu, D., Wang, Y., & Zhou, J. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.007 · Cited by 96

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Wang, S., Song, Y., Yan, F., & Liu, D. (2016) · Frontiers of Medicine · doi:10.1007/s11684-016-0488-1 · Cited by 96

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer

Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96

A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis

Wang, T., Liu, Z., She, Y., Deng, J., Zhong, Y., Zhao, M., Li, S., Xie, D., Sun, X., Hu, X., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.007 · Cited by 96

Tumor‐associated macrophages correlate with response to epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced non‐small cell lung cancer

Chung, F., Lee, K., Wang, C., Heh, C., Chan, Y., Chen, H., Kuo, C.-H. S., Feng, P., Lin, T., Wang, C., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27403 · Cited by 101

Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1 H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers

Lelais, G., Epple, R., Marsilje, T. H., Long, Y. O., McNeill, M., Chen, B., Lu, W., Anumolu, J., Badiger, S., Bursulaya, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01985 · Cited by 95

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

Simonetti, S., Molina‐Vila, M. Á., Queralt, C., de Aguirre, I., Mayo, C., Bertrán-Alamillo, J., Sánchez, J. J., González-Larriba, J. L., Jiménez, U., Isla, D., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-135 · Cited by 95

Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor

Takano, K., Kinoshita, M., Takagaki, M., Sakai, M., Tateishi, S., Achiha, T., Hirayama, R., Nishino, K., Uchida, J., Kumagai, T., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov266 · Cited by 95

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

Li, K., Yang, M., Liang, N., & Li, S. (2017) · Oncology Reports · doi:10.3892/or.2017.5409 · Cited by 95

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156